As brain metastases can occur in different tumor types, especially lung cancer, the potential interaction between selpercatinib and ABCB1/ABCG2 in vivo may not only limit selpercatinib oral exposure but also its brain accumulation, and thus affect therapeutic efficacy for brain metastases in lung cancer patients. Here, ABCG2 is linked to lung carcinoma.